News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Biogen releases further details on how its Phase 4 post-marketing confirmatory study for Alzheimer’s drug, Aduhelm, will run: including increased enrolment and enhanced efforts to encourage diversity.
Eli Lilly and Company will invest $1bn in a new manufacturing facility in North Carolina, US; alongside $500m in a site in Limerick, Ireland.
Gerresheimer is expanding its capacities for glass vials at the Wertheim site in southwestern Germany, and at two further sites in China and the US.
A new California based CDMO has been launched, one that is focused on supporting cell therapy developers.